KELIX bio is a buy-and-build specialty generic business focused on Emerging Markets and designed to compete through innovation and cost leadership. KELIX bio’s purpose is to develop, commercialize affordable specialty products in jurisdictions historically deprived from access to such medications. KELIX bio’s current investors include Development Partners International (“DPI”), CDC Group, the UK’s publicly owned impact investor, and the European Bank for Reconstruction and Development (“EBRD”).